18 results about "Overactive bladder" patented technology

Set forth are vascular valves and servovalves and methods of using the same that may be positioned in the circulatory system without interrupting blood flow to facilitate solid organ transplantation so as to reduce graft organ anoxia and degradation before and after harvesting and storage, thereby minimizing late-term cardiac allograft vasculopathy as a major cause of graft failure. Along the urinary tract, bypassing bladder-generated urge sensation by diverting urine directly from the ureters to a neobladder or collection bag alleviates intractable incontinence, nocturia, urethral syndrome, overactive bladder, dysuria, or frequency. Where the lower tract is missing, a prosthesis can thwart disease and preclude the degenerative metaplastic transition to carcinoma risked when gut is used to construct a conduit for urine, a neobladder, and / or high-maintenance stoma. Druglines to valves and servovalves can directly pipeline-target medication to nidi, anastomoses, or any other trouble spots.

The invention provides a tibial nerve stimulation device and system for treating overactive bladder. The tibial nerve stimulation device comprises a program controller, a pulse generator and a stimulation electrode. The program controller is programmed to be capable of sending out signal parameter setting instructions with the frequency ranging from 500 Hz to 100 kHz, the amplitude ranging from 0.1 mA to 10 mA and the pulse width ranging from 1 us to 1 ms. And the pulse generator is in communication connection with the program controller and is used for generating a specific pulse electric signal according to the signal parameter setting instruction. One end of the stimulating electrode can be implanted into the tibial nerve of a tested object, the other end of the stimulating electrode is electrically connected with the pulse generator, and the stimulating electrode is used for receiving the specific pulse electric signal and transmitting the specific pulse electric signal to the tibial nerve for electrical stimulation. The tibial nerve stimulation device provided by the invention can emit a pulse electric signal with a higher frequency to the tibial nerve, not only can be used for treating overactive bladder, but also can effectively relieve untoward effects such as abnormal feeling or muscle activity of a stimulated part in the treatment process.

Systems and methods provide stimulation of peripheral targets such as targets in the lower limbs. Electrode arrays realized in circumferential or longitudinal embodiments have pads with horizontal and / or vertical offsets. Electrode array geometries are customizable and adaptable to individual users and treatment of different disorders. Novel systems of customization include software and hardware implemented solutions. A single device can provide treatment of two or more disorders or unwanted states using selected electrode geometries and stimulation protocols. Systems and methods for assessment of candidate stimulation sites and protocols use subjective or objective measures or both to determine which meet stimulation success criteria. Simulation is provided using transcutaneous, percutaneous, or implantable stimulators. A main advantage is the improved treatment of pelvic floor disorders, and especially overactive bladder (OAB).

The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

The invention discloses an application of a compound Darifenacin hydrobromide in preparation of a medicine for resisting influenza A (H1N1) virus, and belongs to the technical field of medicines. The invention discloses for the first time that Darifenacin hydrobromide can significantly inhibit replication of H1N1-PR8 virus, reduce virus titer and reduce cytopathic effect (CPE) in an in-vitro cell model, the EC50 value of Darifenacin hydrobromide is 2.5 [mu] M, and the selection index (SI) is gt; and 10, the compound has good antiviral activity and safety. The compound Darifenacin hydrobromide is a high-selectivity M3 muscarinic acetylcholine receptor antagonist and is approved to be used for treating overactive bladder at present, the invention discloses that the compound can inhibit replication and release of H1N1-PR8 virus for the first time, and the compound has a wide prospect of being developed into a medicine for treating human influenza virus infection.

The present invention provides a method and a pharmaceutical composition for the treatment of overactive bladder (OAB) and / or bladder pain syndrome (BPS) comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting / silencing neurotransmission or synaptic transmission of afferent neurons.

To provide a method of treating overactive bladder.SOLUTION: Provided is a method comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.SELECTED DRAWING: Figure 1

The present invention provides improved methods for positioning of an implantable lead in a patient with an integrated EMG and stimulation clinician programmer. The integrated clinician programmer is coupled to the implantable lead, wherein the implantable lead comprises at least four electrodes, and to at least one EMG sensing electrode minimally invasively positioned on a skin surface or within the patient. The method comprises delivering a test stimulation at a stimulation amplitude level from the integrated clinician programmer to a nerve tissue of the patient with a principal electrode of the implantable lead. Test stimulations are delivered at a same stimulation amplitude level for a same period of time sequentially to each of the four electrodes of the implantable lead. A stimulation-induced EMG motor response is recorded with the integrated clinician programmer for each test stimulation on each electrode of the implantable lead via the at least one pair of EMG sensing electrodes so as to facilitate initial positioning of the implantable lead at a target stimulation region.

A neurostimulator is implantable into a body of a subject to treat an overactive bladder condition. The neurostimulator includes a pulse generator, circuitry, a lead, and a connector secured to the lead. The circuitry is disposed within the pulse generator and connected to a battery. The circuitry is configured to generate a stimulation signal with a duty cycle of between 0.1% and 2.5% and a total average current drain from the battery of between 0.1 μA and 5μA, the total average current drain including a background current, plus a stimulation current weighted by the duty cycle. The lead has an electrode assembly configured to direct the generated stimulation signal to tissue of the subject. The connector is adapted to allow the pulse generator to be detachable from and attachable to the lead.

Systems and methods provide stimulation of peripheral targets such as targets in the lower limbs. Electrode arrays realized in circumferential or longitudinal embodiments have pads with horizontal and / or vertical offsets. Electrode array geometries are customizable and adaptable to individual users and treatment of different disorders. Novel systems of customization include software and hardware implemented solutions. A single device can provide treatment of two or more disorders or unwanted states using selected electrode geometries and stimulation protocols. Systems and methods for assessment of candidate stimulation sites and protocols use subjective or objective measures or both to determine which meet stimulation success criteria. Simulation is provided using transcutaneous, percutaneous, or implantable stimulators. A main advantage is the improved treatment of pelvic floor disorders, and especially overactive bladder (OAB).

The present application discloses a brain-computer interface tibial nerve electrical stimulation closed-loop control system, comprising: a scalp electrophysiological monitoring terminal, a tibial nerve electrical stimulation control terminal and a programmable terminal; through the scalp electrophysiological monitoring terminal, scalp electrophysiological signals are monitored in real time in a non-invasive manner, and abnormal signals of overactive bladder are identified when the patient has symptoms of urgency; through the tibial nerve electrical stimulation control terminal, tibial nerve electrical stimulation control is automatically started in response to abnormal signals to achieve on-demand control of the patient at the onset of symptoms of overactive bladder and during the period of symptoms; treatment parameters related to on-demand control are obtained through the programmable terminal, and doctors can configure personalized treatment parameters in a targeted manner according to the displayed information, so as to perform real-time control of tibial nerve electrical stimulation for patients with overactive bladder, effectively improving the accuracy and treatment effect of treatment, reducing treatment time, and improving patient comfort and compliance.

To provide an effective treatment for treating a patient's voiding symptom with less side effects.SOLUTION: In some embodiments, systems and methods can include a wearable device with an electrically conductive skin interface that excites underlying nerves from a transcutaneous surface stimulator. The device may be sized for a range of user sizes with stimulation electrodes positioned to target appropriate nerves, such as the saphenous and / or tibial nerves. Transcutaneous afferent stimulation to one, two, or more peripheral nerves adjust the brain or spinal cord related to a bladder function.SELECTED DRAWING: Figure 1

The invention relates to multi-modal stimulation for treating tremor. A peripheral nerve stimulator is provided that stimulates the peripheral nerve to treat idiopathic tremor and other dyskinesia as well as overactive bladder, cardiac dysfunction, and neurotransmitter dysfunction. The peripheral nerve stimulator may be a non-invasive surface stimulator that provides multi-modal optimized therapy. The stimulation may be vibratory, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, optical, mechanical, chemical, thermal, ultrasonic, radio frequency (RF), acoustic, infrared, ultraviolet, X-ray, and / or microwave. Stimulation may be delivered using an open loop system and / or a closed loop system with feedback. Stimulation may be for one site or several sites.

The invention belongs to the technical field of medical systems, and discloses a system for treating overactive bladder by applying a time domain interference technology, and the system comprises a signal generator which is used for generating two paths of intermediate-frequency AC electric signals, the frequency range of the intermediate-frequency AC electric signals is 1 kHz to 10 kHz, and the frequency difference of the two paths of intermediate-frequency AC electric signals is 1 Hz to 200 Hz; the electrode array is connected with the signal generator and is used for transmitting the two paths of intermediate-frequency alternating-current electric signals to the body surface of the sacral region of the patient; and the control unit is connected with the signal generator and is used for adjusting the frequency difference, the amplitude and the treatment mode of the intermediate-frequency alternating-current electric signal. According to the scheme, a time domain interference technology is used, and intermediate-frequency current and multiple electric field superposition are used, so that tissues can be better penetrated, targeted stimulation of deep sacral nerves is realized, and abnormal activities of the bladder are inhibited. The system supports a static difference frequency mode and a dynamic difference frequency mode, the nerve adaptability is avoided, and the long-term curative effect is improved.

To provide a method of treating overactive bladder in a treatment-experienced subject in need thereof.SOLUTION: The present invention provides a method comprising orally administering to a subject about 75 mg of vibegron per day as a therapeutically effective amount, wherein following administration of vibegron to the subject over a treatment period: a. the decrease in the average number of micturitions in a 24-hour period in the subject is from about 1.5 to about 10 more than the decrease in the average number of micturitions in a subject who receives a placebo; or b. the average number of urge urinary incontinence (UUI) episodes per 24 hours by the subject decreases by from about 1.7 to about 6 times the decrease as that of a subject treated with placebo.SELECTED DRAWING: None

1. Name of the design product: tibial nerve stimulator main machine. 2. Use of the design product: used for discharging tibial nerve to treat overactive bladder and other diseases; or used for stimulating discharge of other nerves. 3. Design points of the design product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

A method of treating a patient having overactive bladder symptoms by a combination of stimulation of the patient's saphenous nerve and the patient's posterior tibial nerve. The method uses a neurostimulator having a computer processor and a signal generator which generates a first stimulation signal which is used to target the patient's saphenous nerve and a second stimulation signal which is used to target the posterior tibial nerve of the patient in accordance with a treatment protocol. The neurostimulator sends the first and second electrical stimulation signals to respective stimulators which then transmit the respective electrical stimulation signals to the patient's saphenous nerve and the patient's posterior tibial nerve in accordance with the stimulation protocol. The first and second stimulators are positioned in locations on the body of the patient to effectively modulate the patient's saphenous nerve and posterior tibial nerve respectively.

Described herein is a crystalline form of a hemihydrate of the β-3 adrenergic receptor agonist vibegron. The disclosure also relates to preparations of the crystalline form, pharmaceutical compositions thereof, methods of making the crystalline form, and methods of using the crystalline form in the treatment of overactive bladder.